Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00252148 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults
A Phase 1 study of HIV Infection, sponsored by International AIDS Vaccine Initiative.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 2
- Study locations
NCT00252148 is a Phase 1 study of HIV Infection that has completed, run by International AIDS Vaccine Initiative. The registered enrollment target is 48 participants, below the 242-participant average among 73 other HIV Infection trials with a reported enrollment target (80% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00252148, a Phase 1 study of HIV Infection, has completed, sponsored by International AIDS Vaccine Initiative.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine the safety of an immune response to an investigational HIV vaccine, ADMVA, at three different dosage levels, in adults who are not infected with HIV
Conditions Studied
Interventions
- BIOLOGICAL ADMVA
Study Locations (2)
New York
- Rockefeller University Hospital - New York
- University of Rochester Medical Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2005-01 |
| Est. Completion | 2007-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00252148
The ClinicalTrials.gov registry entry for NCT00252148 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 73 other HIV Infection trials with a reported enrollment target (80% lower). The listed sponsor is International AIDS Vaccine Initiative, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infection appearing as the primary indexed condition, and to 1 intervention - of which ADMVA is the first listed.
NCT00252148 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00252148 about?
NCT00252148 is a clinical study titled "Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults". The purpose of this study is to determine the safety of an immune response to an investigational HIV vaccine, ADMVA, at three different dosage levels, in adults who are not infected with HIV
What is the current status of trial NCT00252148?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2005-01. Estimated completion is 2007-08.
What conditions does trial NCT00252148 study?
This clinical trial studies the following conditions: HIV Infection.
What interventions are being tested in trial NCT00252148?
The interventions under investigation include: ADMVA (BIOLOGICAL).
Who is sponsoring clinical trial NCT00252148?
This trial is sponsored by International AIDS Vaccine Initiative, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00252148 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
RECRUITING · Phase 1
-
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 1
-
Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption
ACTIVE NOT RECRUITING · Phase 1
-
Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.